Triet Nguyen, Francesca Anna Carrieri, Nick Connis, Audrey Lafargue, Jinhee Chang, Aaron Chan, Amol C Shetty, Yang Song, Tung Hoang, Shreya Jagtap, Dipanwita Dutta Chowdhury, Muhammad Ajmal Khan, Kathleen L Gabrielson, Mohammad Rezaee, Pedro Torres-Ayuso, John Brognard, Christine L Hann, Phuoc T Tran
Most patients with lung squamous cell carcinoma (LSCC) undergo chemotherapy, radiotherapy, and adjuvant immunotherapy for locally advanced disease. The efficacy of these treatments is still limited due to dose-limiting toxicity or locoregional recurrence. New combination approaches and targets such as actionable oncogenic drivers are needed to advance treatment options for LSCC patients. Moreover, other options for chemotherapy-ineligible patients are also limited. As such there is a critical need for the development of selective and potent chemoradiosensitizers for locally advanced LSCC...
April 27, 2024: Molecular Cancer Therapeutics